Lundin Law PC announces a class action lawsuit has been filed against Amicus Therapeutics, Inc. (“Amicus” or the “Company”) (FOLD) concerning possible violations of federal securities laws between September 15, 2015 and October 1, 2015. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the December 7, 2015, lead plaintiff motion deadline.
To participate in this class action lawsuit, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via e-mail at brian@lundinlawpc.com.
According to the complaint, on October 2, 2015, Amicus announced that after meeting with FDA officials, the Company does not anticipate being able to submit a new drug application (NDA) for migalastat, the company's Fabry disease treatment, by the end of the year. When the truth was revealed, shares dropped, harming investors.
No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151126005540/en/
Contacts:
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile:
888-713-1125
brian@lundinlaw.com
